“Always professional and engaging while getting me in and out quickly. Dr. Rial is the man!”
Why Your Insurance Makes You Try Avastin Before Eylea for Diabetic Macular Edema
How These Two Drugs Work Inside the Eye
Avastin and Eylea are both injected directly into the eye and work by blocking the same growth signal, but they are different molecules with different FDA approval histories. Understanding those differences makes the insurance rule easier to follow and easier to challenge when needed.
Diabetic macular edema is swelling in the macula, the small central area of the retina you rely on for reading, recognizing faces, and seeing fine detail. Diabetes damages the tiny blood vessels in the retina until they leak fluid into that central zone. The blurring tends to affect the center of your vision while side vision stays clear, which can feel oddly specific.
This condition is common. About one in fifteen people with diabetes develops this type of swelling, and more than half of all people with diabetes develop some form of diabetic retinopathy over their lifetime. Because it is so prevalent, it is also one of the most carefully studied conditions in retinal medicine, and the treatments are well established.
Avastin is the brand name for bevacizumab, a drug that blocks VEGF, the signal that drives abnormal and leaky blood vessel growth. It is given as a small injection into the eye after numbing drops are applied. The procedure takes only a few minutes in the office.
Avastin is not FDA-approved for any eye condition. The FDA approved bevacizumab for cancer treatment, and eye doctors use it off-label for retinal disease. Off-label use is legal and common when strong evidence supports it, and bevacizumab has been used in eyes since 2005. Because the cancer vial is far larger than an eye dose, a compounding pharmacy divides it into single-dose syringes before it reaches your clinic.
Eylea is the brand name for aflibercept, a different VEGF-blocking molecule built as a molecular trap. Unlike bevacizumab, Eylea is FDA-approved specifically for diabetic macular edema. The standard labeled schedule calls for injections every four weeks for the first five doses, then once every eight weeks, though your retina specialist may adjust that interval based on what your scans show.
That FDA approval is the key difference your insurer is focused on. One drug is officially approved for your diagnosis and one is not, even though both are widely used and well studied in the eye.
Both drugs disrupt the same leaky-vessel signaling pathway, which is why insurers consider them interchangeable enough to try in order. Think of them as two tools built for the same job, one with a slight molecular advantage in certain eyes. Aflibercept binds VEGF more tightly and also blocks a related signal called placental growth factor, which may explain why it tends to perform a little better in eyes with more significant vision loss at the start of treatment.
That difference shows up in some eyes and not others, and the clinical trials below explored exactly when it matters most.
How Step Therapy Works in Practice
Step therapy is a coverage policy, not a medical protocol. Knowing its rules, including the limits on what a plan can actually require, gives you and your retina specialist the information needed to navigate it effectively.
The word fail sounds alarming, but here it simply means your eye did not improve enough by an agreed measure. You did nothing wrong. In the clinical trial that tested this sequence, an eye was eligible to switch from bevacizumab to aflibercept starting at week 12 when retinal swelling persisted, the eye had received enough injections already, vision was still below a set level, and neither vision nor retinal thickness had improved enough over prior visits.
Your clinic tracks three key numbers at each visit: your eye chart score, your retinal thickness from the scan, and how many injections you have had. Ask to see those numbers so you know where you stand.
Federal rules allow Medicare Advantage plans to apply step therapy to Part B drugs, which includes in-office injections like these. But the rules also set limits. A plan may only apply step therapy to new administrations of a drug, using a lookback period of at least 365 days, and its policy must be based on scientific evidence and standards of care.
That lookback period matters to you directly. If you have been receiving Eylea within the past year, the plan is generally not permitted to move you back to a different drug.
You do not have to wait passively for the rule to run its course. Retina specialists commonly respond to these policies by filing a formal exception request or requesting a peer-to-peer discussion with the plan's medical director. Starting that process early beats starting it after a denial letter arrives.
Plans typically accept a documented poor response to the first drug, a reaction to the drug, or a clear medical reason it is a poor fit. Your retina specialist's office knows the clinical language your plan expects, so ask them to take the lead on filing.
What the Clinical Trials Found
Two major clinical trials from the DRCR Retina Network directly tested these drugs and this sequence. Their findings are what both your insurer and your retina specialist are drawing on when they discuss your options.
This large head-to-head trial compared bevacizumab, aflibercept, and a third drug called ranibizumab directly against one another. The overall two-year results showed aflibercept averaging more vision gain than bevacizumab, but the picture split clearly by starting vision level. In eyes that started with only mild vision loss, averaging around 20/32 to 20/40, gains across all three drugs were similar and the differences were not statistically meaningful. In eyes starting with moderate vision loss, around 20/50 to 20/320, aflibercept averaged meaningfully more gain than bevacizumab when used alone.
That finding is useful. If your vision loss is mild at the start of treatment, the two drugs performed about equally on average. If your loss is more significant, aflibercept had an edge when used on its own, which is exactly where the question of sequencing becomes more important.
This later trial was designed specifically to test the sequence your insurance plan is asking for. It enrolled adults with moderate vision loss and randomly assigned them to either aflibercept alone or bevacizumab first with the option to switch. At two years, the average vision improvement was 15.0 letters with aflibercept alone and 14.0 letters with bevacizumab first. The adjusted difference of 0.8 letters fell within a statistical range that includes no difference at all. About 70 out of every 100 eyes in the bevacizumab-first group ended up switching to aflibercept at some point.
Eyes that met the switch criteria and moved to aflibercept gained additional vision after the change. That is the reassuring finding, and it is also a reminder that the switch needs to happen promptly when the eye signals it is needed.
Averages describe groups, not individuals. Some eyes clear on bevacizumab and stay clear for years without ever switching. Others hold fluid from the first injection and respond only after the drug changes. A one-letter difference in a group average does not predict either outcome for your eye.
These trials also ran on strict visit schedules. The safety of a start-cheap approach depends on close monitoring, and missed visits remove the safety net that makes the sequence reasonable in the first place.
Costs, Risks, and a Realistic Outlook
The price gap between these two drugs is the engine behind this entire policy. Understanding what treatment costs, what risks come with it, and what it can realistically achieve helps you make informed decisions at every step.
Based on Medicare payment data, one dose of bevacizumab costs roughly 70 dollars while one dose of aflibercept costs roughly 1,800 dollars. Modeled two-year treatment costs per patient were approximately 19,000 dollars for a bevacizumab-first approach compared to roughly 32,000 dollars for aflibercept alone. Those are plan costs, not necessarily your personal out-of-pocket bill.
Under Medicare Part B, your coinsurance is typically a share of the drug's cost, which means a cheaper drug can also mean a smaller bill for you. Ask your clinic's billing staff to estimate your expected share for each drug before deciding how hard to pursue an exception.
The risks of these treatments come primarily from the injection itself rather than from which drug is being used. Common effects include temporary redness, mild irritation, and brief blurring after the procedure. Serious complications are rare and include infection inside the eye, a condition called endophthalmitis, and retinal detachment.
Pooled analyses of large numbers of injections found infection rates well below one in a thousand. The most important thing to know is that early treatment gives an infected eye its best chance of recovery, which is why calling your doctor the same day you notice worsening pain or a sudden drop in vision is so important.
The risk in step therapy is not the first drug. It is the gap between the day your eye stops responding and the day the right drug reaches it. The trial that tested this sequence addressed this by building its switch criteria in from week 12 rather than leaving the waiting period open-ended.
You can shrink that gap by keeping every visit, reporting any new blurring promptly, and asking your clinic to file the exception request the same week you meet the criteria. Speed on the paperwork protects your vision.
For most people, these injections are a long-term management strategy rather than a short course of treatment. In the trials above, average vision improved by roughly two to three lines on an eye chart over two years, with injections continuing throughout that period. Some people gain more, some gain less, and some hold steady. Holding steady is a meaningful result when the alternative is ongoing vision loss.
Blood sugar and blood pressure control continue to matter alongside treatment. The injections address the leaking that is already happening, while good diabetes management shapes how hard they have to work over time.
When to Call Between Injections
Most people feel mild soreness or see a temporary red spot on the white of the eye after an injection, and both typically resolve within a day or two. A few situations require a same-day call to your retina specialist, and knowing them in advance is part of staying safe during treatment.
Do not wait for your next scheduled appointment if you notice any of the following after an injection.
- Eye pain that worsens after the first day rather than improving
- A noticeable drop in vision in the treated eye
- Increasing redness with sensitivity to light
- A sudden increase in floaters, flashes of light, or a dark curtain or shadow across your vision
Infection after an injection typically announces itself within one to six days with eye pain and redness alongside falling vision. Treated quickly, many eyes recover well. That is why the same-day call is so important rather than waiting to see if symptoms improve on their own.
Some changes are not emergencies but should not wait months for a scheduled slot. Call your office within a few days if reading becomes harder than usual, if straight lines appear bent or wavy, or if a blurred patch in your central vision grows larger.
These are also the signs that your eye may be ready for a switch in treatment. Reporting them early protects your vision and creates the documented record your exception request will need if your plan requires one.
Frequently Asked Questions
These questions address specific situations and decisions that come up during step therapy, going beyond the general explanations covered above.
No. They are entirely different molecules that happen to block the same growth signal. The lower cost reflects how bevacizumab is manufactured and distributed, not a weaker formula. In eyes with mild starting vision loss, the two drugs produced nearly identical average results in head-to-head testing. The advantage of aflibercept showed up specifically in eyes that started with more significant vision loss when that drug was used alone from the beginning, rather than in a sequence.
Generally yes, within defined limits. Federal rules allow Medicare Advantage plans to apply step therapy to Part B injections, but only for new administrations, only using a lookback of at least one year, and only when the policy is grounded in scientific evidence. If you have been receiving Eylea continuously within the past year, the plan typically cannot require you to restart on a different drug. Commercial plans set their own versions of these rules. In either case, you always retain the right to formally request an exception.
There is no single number set by law. Your specific plan's coverage criteria determine this, and those vary. In the clinical trial that tested this sequence, eyes became eligible to switch starting at week 12 when swelling persisted, enough injections had been given, vision remained below a defined level, and neither vision nor retinal thickness had improved adequately over recent visits. Ask your retina specialist's office to walk you through the exact criteria your plan uses so there are no surprises when the time comes.
Ask your retina specialist's office to file a formal exception request with your documented response on record. If that request is denied, ask for a peer-to-peer discussion between your retina specialist and the plan's medical director. Get the denial in writing, note the appeal deadline, and ask what treatment will continue while the appeal is under review. Starting this process early rather than after a denial produces faster results.
Typically not. Medicare Advantage step therapy applies to new administrations of a Part B drug and uses a lookback window of at least one year, meaning patients already on ongoing treatment generally fall outside its scope. If you switch insurance plans and receive a letter suggesting you must restart on a different drug, notify your retina specialist's office immediately so they can document your treatment history and respond to the plan directly.
It is possible, but the cost is substantial per dose and treatment typically continues for a year or more, so self-pay is rarely practical as a long-term solution. Before going that route, ask your retina specialist whether your eye already meets the clinical criteria for a switch, because a well-documented exception request may get the same drug covered within days. Manufacturer assistance programs and supplemental coverage can sometimes close the gap as well, and your clinic's billing staff can help you explore those options.
Visit Atlantic Retina Center
At Atlantic Retina Center, our fellowship-trained, ABO board-certified retina specialists focus exclusively on the retina, vitreous, and macula, giving every patient the full benefit of a single-specialty practice. We perform serial retinal photo comparisons at every visit to track your eye over time, and we are experienced in navigating insurance step therapy on behalf of our patients when a switch is clinically appropriate. If you have been diagnosed with diabetic macular edema or have questions about your current injection treatment, we encourage you to reach out and schedule an appointment with our team.